The symptom phenotype of oncology outpatients remains relatively stable from prior to through 1 week following chemotherapy

European Journal of Cancer Care

Volumn 26, Issue 3, 2017, Pages

  Miaskowski, C ^a   Cooper, B A ^a   Aouizerat, B ^b   Melisko, M ^c   Chen, L M ^c   Dunn, L ^c   Hu, X ^a   Kober, K M ^a   Mastick, J ^a   Levine, J D ^c   Hammer, M ^d   Wright, F ^e   Harris, J ^f   Armes, J ^f   Furlong, E ^g   Fox, P ^g   Ream, E ^h   Maguire, R ^h   Kearney, N ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e YALE UNIVERSITY   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY COLLEGE DUBLIN   (Ireland)

^h UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

cancer; chemotherapy; latent transition analysis; predictive risk modelling; quality of life; symptoms

Indexed keywords

CHILD; CHILD CARE; COMORBIDITY; CONTROLLED STUDY; DRUG DOSAGE FORM; FUNCTIONAL STATUS; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; ONCOLOGY; OUTPATIENT; PHENOTYPE; PROBABILITY; QUALITY OF LIFE; RESPONSIBILITY; SYMPTOM; SYMPTOM ASSESSMENT; ADOLESCENT; ADULT; AGED; AMBULATORY CARE; CLINICAL TRIAL; FEMALE; HEALTH STATUS; MALE; MENTAL HEALTH; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; STATISTICS AND NUMERICAL DATA; TIME FACTOR; YOUNG ADULT;

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC AGENTS; FEMALE; HEALTH STATUS; HUMANS; MALE; MENTAL HEALTH; MIDDLE AGED; NEOPLASMS; OUTPATIENTS; PHENOTYPE; QUALITY OF LIFE; TIME FACTORS; YOUNG ADULT;

EID: 84955057716     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/ecc.12437     Document Type: Article

References (57)

1. Baldwin C.M., Ervin A.M., Mays M.Z., Robbins J., Shafazand S., Walsleben J. & Weaver T. (2010) Sleep disturbances, quality of life, and ethnicity: the sleep heart health study. Journal of Clinical Sleep Medicine 6, 176–183.
2. Bastanlar Y. & Ozuysal M. (2014) Introduction to machine learning. Methods in Molecular Biology 1107, 105–128.
3. Cataldo J.K., Paul S., Cooper B., Skerman H., Alexander K., Aouizerat B., Blackman V., Merriman J., Dunn L., Ritchie C., Yates P. & Miaskowski C. (2013) Differences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study. BMC Cancer 13, 6.
4. Celeux G. & Soromenho G. (1996) An entropy criterion for assessing the number of clusters in a mixture model. Journal of Classification 13, 195–212.
5. Cheong J., Mackinnon D.P. & Khoo S.T. (2003) Investigation of mediational processes using parallel process latent growth curve modeling. Structural Equation Modeling – A Multidisciplinary Journal 10, 238–262.
6. Cheung W.Y., Le L.W., Gagliese L. & Zimmermann C. (2011) Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer. Supportive Care in Cancer 19, 417–423.
7. Collins L.M. & Lanza S.T. (2010) Latent Class and Latent Transition Analysis: With Applications in the Social, Behavioral, and Health Science. John Wiley & Sons, Hoboken, NJ, USA.
8. Collins F.S. & Varmus H. (2015) A new initiative on precision medicine. New England Journal of Medicine 372, 793–795.
9. Coppede F. (2013) The epidemiology of premature aging and associated comorbidities. Clinical Interventions in Aging 8, 1023–1032.
10. Dantzer R. (2006) Cytokine, sickness behavior, and depression. Neurology Clinics 24, 441–460.
11. Dantzer R., O'connor J.C., Freund G.G., Johnson R.W. & Kelley K.W. (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience 9, 46–56.
12. Dodd M.J., Cho M.H., Cooper B.A. & Miaskowski C. (2010) The effect of symptom clusters on functional status and quality of life in women with breast cancer. European Journal of Oncology Nursing 14, 101–110.
13. Dodd M.J., Cho M.H., Cooper B.A., Petersen J., Bank K.A., Lee K.A. & Miaskowski C. (2011) Identification of latent classes in patients who are receiving biotherapy based on symptom experience and its effect on functional status and quality of life. Oncology Nursing Forum 38, 33–42.
14. Dow K.H., Ferrell B.R., Leigh S., Ly J. & Gulasekaram P. (1996) An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Research and Treatment 39, 261–273.
15. Esther Kim J.E., Dodd M.J., Aouizerat B.E., Jahan T. & Miaskowski C. (2009) A review of the prevalence and impact of multiple symptoms in oncology patients. Journal of Pain and Symptom Management 37, 715–736.
16. Ferreira K.A., Kimura M., Teixeira M.J., Mendoza T.R., Da Nobrega J.C., Graziani S.R. & Takagaki T.Y. (2008) Impact of cancer-related symptom synergisms on health-related quality of life and performance status. Journal of Pain and Symptom Management 35, 604–616.
17. Ferrell B.R., Dow K.H. & Grant M. (1995) Measurement of the quality of life in cancer survivors. Quality of Life Research 4, 523–531.
18. Gwede C.K., Small B.J., Munster P.N., Andrykowski M.A. & Jacobsen P.B. (2008) Exploring the differential experience of breast cancer treatment-related symptoms: a cluster analytic approach. Supportive Care in Cancer 16, 925–933.
19. Harrison N.A., Brydon L., Walker C., Gray M.A., Steptoe A. & Critchley H.D. (2009) Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biological Psychiatry 66, 407–414.
20. Illi J., Miaskowski C., Cooper B., Levine J.D., Dunn L., West C., Dodd M., Dhruva A., Paul S.M., Baggott C., Cataldo J., Langford D., Schmidt B. & Aouizerat B.E. (2012) Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. Cytokine 58, 437–447.
21. Karnofsky D. (1977) Performance Scale. Plenum Press, New York, NY, USA.
22. Kearney N., Mccann L., Norrie J., Taylor L., Gray P., Mcgee-Lennon M., Sage M., Miller M. & Maguire R. (2009) Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity. Supportive Care in Cancer 17, 437–444.
23. Kirkova J., Rybicki L., Walsh D. & Aktas A. (2012) Symptom prevalence in advanced cancer: age, gender, and performance status interactions. American Journal of Hospice and Palliative Care 29, 139–145.
24. Kong C.M., Lee X.W. & Wang X. (2013) Telomere shortening in human diseases. FEBS Journal 280, 3180–3193.
25. Kumar A., Soares H.P., Balducci L., Djulbegovic B. & National Cancer I (2007) Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. Journal of Clinical Oncology 25, 1272–1276.
26. Lanza S.T., Flaherty B.P. & Collins L.M. (2003) Latent class and latent transition analysis. In: Handbook of Psychology: Research Methods in Psychology (eds Schinka J.A. & Velicer W.F.), pp. 663–685. John Wiley & Sons, Hoboken, NJ, USA.
27. Maguire R., Ream E., Richardson A., Connaghan J., Johnston B., Kotronoulas G., Pedersen V., Mcphelim J., Pattison N., Smith A., Webster L., Taylor A. & Kearney N. (2015) Development of a novel remote patient monitoring system: the advanced symptom management system for radiotherapy to improve the symptom experience of patients with lung cancer receiving radiotherapy. Cancer Nursing 38, E37–47.
28. Menck C.F. & Munford V. (2014) DNA repair diseases: what do they tell us about cancer and aging? Genetic and Molecular Biology 37, 220–233.
29. Miaskowski C. (2004) Gender differences in pain, fatigue, and depression in patients with cancer. Journal of the National Cancer Institute 32, 139–143.
30. Miaskowski C., Cooper B.A., Paul S.M., Dodd M., Lee K., Aouizerat B.E., West C., Cho M. & Bank A. (2006) Subgroups of patients with cancer with different symptom experiences and quality-of-life outcomes: a cluster analysis. Oncology Nursing Forum 33, E79–89.
31. Miaskowski C., Cooper B.A., Melisko M., Chen L.M., Mastick J., West C., Paul S.M., Dunn L.B., Schmidt B.L., Hammer M., Cartwright F., Wright F., Langford D.J., Lee K. & Aouizerat B.E. (2014a) Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. Cancer 120, 2371–2378.
32. Miaskowski C., Paul S.M., Cooper B., West C., Levine J.D., Elboim C., Hamolsky D., Abrams G., Luce J., Dhruva A., Langford D.J., Merriman J.D., Kober K., Baggott C., Leutwyler H. & Aouizerat B.E. (2014b) Identification of patient subgroups and risk factors for persistent arm/shoulder pain following breast cancer surgery. European Journal of Oncology Nursing 18, 242–253.
33. Miaskowski C., Dunn L., Ritchie C., Paul S.M., Cooper B., Aouizerat B.E., Alexander K., Skerman H. & Yates P. (2015) Latent class analysis reveals distinct subgroups of patients based on symptom occurrence and demographic and clinical characteristics. Journal of Pain and Symptom Management 50, 28–37.
34. Muthen L.K. & Muthen B.O. (1998-2014) Mplus User's Guide (7th ed.), 7th edn. Muthen & Muthen, Los Angeles, CA, USA.
35. Muthen B. & Shedden K. (1999) Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics 55, 463–469.
36. Myers J.S. (2008) Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncology Nursing Forum 35, 802–807.
37. Nylund K., Bellmore A., Nishina A. & Graham S. (2007a) Subtypes, severity, and structural stability of peer victimization: what does latent class analysis say? Child Development 78, 1706–1722.
38. Nylund K.L., Asparouhov T. & Muthen B.O. (2007b) Deciding on the number of classes in latent class analysis and growth mixture modeling: A Monte Carlo simulation study. Structural Equation Modeling 14, 535–569.
39. Oksholm T., Rustoen T., Cooper B., Paul S. M., Solberg S., Henriksen K., Kongerud J. S. & Miaskowski C. (2015) Trajectories of symptom occurrence and severity from before through five months after lung cancer surgery. Journal of Pain and Symptom Management 49, 995–1015.
40. Osoba D. (1999) Interpreting the meaningfulness of changes in health-related quality of life scores: lessons from studies in adults. International Journal of Cancer 12, 132–137.
41. Portenoy R.K., Thaler H.T., Kornblith A.B., Lepore J.M., Friedlander-Klar H., Kiyasu E., Sobel K., Coyle N., Kemeny N. & Norton L., H. Scher et al. (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. European Journal of Cancer 30A, 1326–1336.
42. Pud D., Ben Ami S., Cooper B.A., Aouizerat B.E., Cohen D., Radiano R., Naveh P., Nikkhou-Abeles R., Hagbi V., Kachta O., Yaffe A. & Miaskowski C. (2008) The symptom experience of oncology outpatients has a different impact on quality-of-life outcomes. Journal of Pain and Symptom Management 35, 162–170.
43. Ritchie C., Dunn L.B., Paul S.M., Cooper B.A., Skerman H., Merriman J.D., Aouizerat B., Alexander K., Yates P., Cataldo J. & Miaskowski C. (2014) Differences in the symptom experience of older oncology outpatients. Journal of Pain and Symptom Management 47, 697–709.
44. Rose J.H., Kypriotakis G., Bowman K.F., Einstadter D., O'toole E.E., Mechekano R. & Dawson N.V. (2009) Patterns of adaptation in patients living long term with advanced cancer. Cancer 115, 4298–4310.
45. Sangha O., Stucki G., Liang M.H., Fossel A.H. & Katz J.N. (2003) The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis and Rheumatism 49, 156–163.
46. Schwartz C.E. & Sprangers M.A. (1999) Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Social Science and Medicine 48, 1531–1548.
47. Sloan J.A., Cella D., Frost M.H., Guyatt G. & Osoba D. (2003) Quality of life III: translating the science of quality-of-life assessment into clinical practice-an example-driven approach for practicing clinicians and clinical researchers. Clinical Therapeutics 25(Suppl. D), D1–5.
48. Sprangers M.A. & Schwartz C.E. (1999) The challenge of response shift for quality-of-life-based clinical oncology research. Annals of Oncology 10, 747–749.
49. Stanton A.L., Rowland J.H. & Ganz P.A. (2015) Life after diagnosis and treatment of cancer in adulthood: contributions from psychosocial oncology research. American Psychologist 70, 159–174.
50. Teschendorff A.E., West J. & Beck S. (2013) Age-associated epigenetic drift: implications, and a case of epigenetic thrift? Human Molecular Genetics 22, R7–R15.
51. Townsley C., Pond G.R., Peloza B., Kok J., Naidoo K., Dale D., Herbert C., Holowaty E., Straus S. & Siu L.L. (2005) Analysis of treatment practices for elderly cancer patients in Ontario, Canada. Journal of Clinical Oncology 23, 3802–3810.
52. Trudel-Fitzgerald C., Savard J. & Ivers H. (2012) Evolution of cancer-related symptoms over an 18-month period. Journal of Pain and Symptom Management 45, 1007–1018.
53. Vermunt J.K. & Magdison J. (2002) Latent Class Cluster Analyses. Cambridge University Press, New York, NY, USA.
54. Walker A.K., Kavelaars A., Heijnen C.J. & Dantzer R. (2014) Neuroinflammation and comorbidity of pain and depression. Pharmacology Reviews 66, 80–101.
55. Wang X.S., Shi Q., Williams L.A., Mao L., Cleeland C.S., Komaki R.R., Mobley G.M. & Liao Z. (2010) Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behavior and Immunity 24, 968–974.
56. Ware J. Jr, Kosinski M. & Keller S.D. (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Medical Care 34, 220–233.
57. Yoo C., Ramirez L. & Liuzzi J. (2014) Big data analysis using modern statistical and machine learning methods in medicine. International Neurourology Journal 18, 50–57.